Summary
Drug manufacturers are concerned as the Trump administration considers linking U.S. medicine prices to those of other developed nations, a policy viewed as a significant threat to the pharmaceutical industry and U.S. biosciences innovation. The proposal, referred to as international reference pricing, could disrupt the healthcare market and has been suggested to stem from the agency overseeing Medicare and Medicaid. Previous attempts to implement similar pricing strategies faced legal challenges, while current negotiations for drug prices under Biden’s administration still reveal stark price disparities between the U.S. and other countries.
